Copyright © 2004 by the European Society of Cardiology.
Clinical research
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
a Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche ‘Mario Negri’,Milan, Italy
b Cardiology Section, V.A. Medical Centre,Minneapolis, Minnesota, USA
c Novartis Pharmaceuticals Corporation,East Hanover, New Jersey, USA
d Cardiovascular Division, Department of Medicine, University of Minnesota Medical School,Minneapolis, Minnesota, USA
e Centro Studi ANMCO,Florence, Italy
* Correspondence to: Dr. Roberto Latini, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via Eritrea 62, 20157 Milan, Italy. Tel: +39.0239014454; Fax: +39 0233200049
E-mail address: latini{at}marionegri.it
Received 29 January 2003;
revised 1 October 2003;
accepted 30 October 2003
See page 281, for the editorial comment on this article
Abstract
Aims Plasma levels of individual neurohormones (NH) have been proposed as reliable indicators for risk stratification of patients with heart failure (HF). Mainly because of small sample size, the predictive value of different NH has never been compared, while taking into account demographic, clinical and echocardiographic markers of risk in HF.
Methods and results Plasma brain natriuretic peptide (BNP), norepinephrine (NE), renin activity (PRA), aldosterone (aldo) and endothelin were measured in 4300 patients before randomization in Val-HeFT. Univariate and multivariate Cox proportional hazard analyses were performed to investigate the relationship between NH and two primary study outcomes, mortality and combined mortality and morbidity (M/M). Higher baseline values for all NH were related to mortality and M/M, with univariate hazard ratios ranging from 1.13 [95% CI 0.99–1.30] (aldo) to 2.47 [2.13–2.87] (BNP) for mortality, and from 1.24 [1.11–1.39] (aldo) to 2.56 [2.28–2.89] (BNP) for M/M. In multivariate analyses, BNP had the strongest association with outcome, followed by NE and PRA. Patients with more activation of renin-angiotensin-aldosterone system tended to show greater benefit from valsartan; but the trend was not statistically significant.
Conclusion All the NHs evaluated in 4300 patients with stable moderate to severe HF were found to be significant markers of outcome, despite therapy with ACEi, BB and randomization to an angiotensin receptor blocker or placebo. Several of these markers have been implicated as contributors to progression of HF, but BNP, which is thought to be protective, was the most powerful indicator for poor outcome.
Key Words: Heart failure • Neurohormones • Outcome • Brain natriuretic peptide • Norepinephrine • Aldosterone • Renin • Endothelin
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Neurohormones in heart failure: predicting outcomes, optimizing care
- Michael M. Givertz and Eugene Braunwald
EHJ 2004 25: 281-282.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  M. Yamaji, T. Tsutamoto, C. Kawahara, K. Nishiyama, T. Yamamoto, M. Fujii, and M. Horie Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure: The Impact of Oxidative Stress Circ Heart Fail, November 1, 2009; 2(6): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Andersen, M. H Weinberger, C. M Constance, M. A Ali, J. Jin, M. F Prescott, and D. L Keefe Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 157 - 167. [Abstract] [PDF]
|
|
|
|
|
|
S. Bansal, J. Lindenfeld, and R. W. Schrier Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? Circ Heart Fail, July 1, 2009; 2(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kubanek, K. M. Goode, V. Lanska, A. L. Clark, and J. G.F. Cleland The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction Eur J Heart Fail, April 1, 2009; 11(4): 367 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Solomon, E. Appelbaum, W. J. Manning, A. Verma, T. Berglund, V. Lukashevich, C. Cherif Papst, B. A. Smith, B. Dahlof, and for the Aliskiren in Left Ventricular Hypertrophy Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy Circulation, February 3, 2009; 119(4): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McMurray, M. Petrie, K. Swedberg, M. Komajda, S. Anker, and R. Gardner CHAPTER 23 Heart Failure ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, K. Nishiyama, H. Sakai, T. Tanaka, M. Fujii, T. Yamamoto, M. Yamaji, and M. Horie Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure Eur J Heart Fail, December 1, 2008; 10(12): 1208 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Nieminen, J. G.F. Cleland, J. Eha, Y. Belenkov, M. Kivikko, P. Poder, and T. Sarapohja Oral levosimendan in patients with severe chronic heart failure--The PERSIST study Eur J Heart Fail, December 1, 2008; 10(12): 1246 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E.A. Blair, F. Zannad, M. A. Konstam, T. Cook, B. Traver, J. C. Burnett Jr, L. Grinfeld, H. Krasa, A. P. Maggioni, C. Orlandi, et al. Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure: Results From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Program J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1640 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo Cardiorenal Syndrome J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1527 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Richards Serial Measurements of Plasma B-Type Natriuretic Peptides: What Do They Tell Us? J. Am. Coll. Cardiol., September 16, 2008; 52(12): 1004 - 1005. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, D. L. Keefe, J. Ford, A. Verma, J. Lewsey, and for the Aliskiren Observation of Heart Failure Tre Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure Circ Heart Fail, May 1, 2008; 1(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J T Parissis, M Nikolaou, D Farmakis, V Bistola, I A Paraskevaidis, S Adamopoulos, G Filippatos, and D T Kremastinos Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure Heart, May 1, 2008; 94(5): 585 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Whalley, S. P. Wright, A. Pearl, G. D. Gamble, H. J. Walsh, M. Richards, and R. N. Doughty Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community Eur. Heart J., February 2, 2008; 29(4): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O.W. Nielsen, P.J. Cowburn, A. Sajadieh, J.J. Morton, H. Dargie, and T. McDonagh Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care Eur J Heart Fail, December 1, 2007; 9(12): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Latini, S. Masson, I. S. Anand, E. Missov, M. Carlson, T. Vago, L. Angelici, S. Barlera, G. Parrinello, A. P. Maggioni, et al. Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure Circulation, September 11, 2007; 116(11): 1242 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Cohn Myocardial Structural Effects of Aldosterone Receptor Antagonism in Heart Failure J. Am. Coll. Cardiol., August 14, 2007; 50(7): 597 - 599. [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, T. Tanaka, H. Sakai, C. Ishikawa, M. Fujii, T. Yamamoto, and M. Horie Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure Eur. Heart J., July 2, 2007; 28(14): 1723 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Naegeli, D. J. Kurz, D. Koller, E. Straumann, M. Furrer, D. Maurer, E. Minder, and O. Bertel Single-chamber ventricular pacing increases markers of left ventricular dysfunction compared with dual-chamber pacing Europace, March 1, 2007; 9(3): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pitzalis, M. Iacoviello, M. Anaclerio, C. Forleo, F. Di Serio, L. Varraso, and N. Pansini Methodical approach to collecting and preserving plasma samples containing B-type natriuretic peptide Eur J Heart Fail, February 1, 2007; 9(2): 215 - 215. [Full Text] [PDF]
|
|
|
|
|
|
M. Kubanek, I. Malek, J. Bytesnik, P. Fridl, L. Riedlbauchova, L. Karasova, V. Lanska, and J. Kautzner Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months Eur J Heart Fail, December 1, 2006; 8(8): 832 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Mikkelsen, J. E. Moller, P. Bie, H. Ryde, L. Videbaek, and T. Haghfelt Tei index and neurohormonal activation in patients with incident heart failure: Serial changes and prognostic value Eur J Heart Fail, October 1, 2006; 8(6): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Roig Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E12 - E17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al. Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data Clin. Chem., August 1, 2006; 52(8): 1528 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure Heart, May 1, 2006; 92(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Levy, D. Mozaffarian, D. T. Linker, S. C. Sutradhar, S. D. Anker, A. B. Cropp, I. Anand, A. Maggioni, P. Burton, M. D. Sullivan, et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure Circulation, March 21, 2006; 113(11): 1424 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, and P. Hildebrandt Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure Circulation, September 20, 2005; 112(12): 1756 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Avgeropoulou, I. Andreadou, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, and I. Kallikazaros The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine Eur J Heart Fail, August 1, 2005; 7(5): 882 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Gardner, V. Chong, I. Morton, and T. A. McDonagh N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-{alpha} in patients referred for consideration of cardiac transplantation Eur J Heart Fail, March 2, 2005; 7(2): 253 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction J. Am. Coll. Cardiol., March 1, 2005; 45(5): 661 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Conraads, P. Beckers, J. Vaes, M. Martin, V. Van Hoof, C. De Maeyer, N. Possemiers, F. L. Wuyts, and C. J. Vrints Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure Eur. Heart J., October 2, 2004; 25(20): 1797 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Givertz and E. Braunwald Neurohormones in heart failure: predicting outcomes, optimizing care Eur. Heart J., February 2, 2004; 25(4): 281 - 282. [Full Text] [PDF]
|
|